Pharvaris
pharvaris.comLocations
Zug, Switzerland
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Other
founded in
2015
Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing with new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediatedindications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study.
Something looks off?Open jobs at Pharvaris
On-site & Remote
Job function